NCT03383419View on ClinicalTrials.gov

Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 20, 2018

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions
Heart Failure
Interventions
DRUG

Epclusa

If and when these recipients develop confirmed viremia by HCV PCR, Epclusa® therapy will be administered for a 12-week course.

Trial Locations (3)

27705

Duke University Medical Center, Durham

75246

Baylor University Medical Center, Dallas

90048

Cedars-Sinai Medical Center, Los Angeles

Sponsors
All Listed Sponsors
lead

Baylor Research Institute

OTHER